Page 522 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Appendix Table C4.3. Comparison between watchful waiting and radiation therapy (continued)
Author, Year Study name Comparison Outcome Followup Sample size Results Factors included in the
[Pubmed ID] /Database definition/ (yr) per group model
measurement
Study design instrument
Quality of life
Fransson 225 Ancillary RT vs. WW Prostate Median RT: 27 No statistically significant For the mean scores
2009 investigation Cancer followup WW: 27 differences in health-related univariate non-parametric
18985545 from UMEA1 Symptom (range): QoL function or symptom (Mann-Whitney) tests were
trial Scale; WW, 114 scales. No differences were used (RCT). MANOVA
RCT European mo (95- detected between RT analyses did not detect any
Organization 196); RT, (mean=2.3) and WW (mean = associations between
for Research 118 mo 2.3; P=NR) for “limitations in overall QoL/health, urinary
and Treatment (77-188) daily life” caused by prostate bother, bowel bother and
of Cancer cancer. No significant difference sexual bother (dependent
QLQ-C30 in “life situation” between RT variables) and age, RT dose
(functioning (mean=3.7) and WW (RT group only), progress
and single (mean=3.3; P=0.398). (RT and WW), hormones
symptom (RT and WW), diabetes, or
scales) Mean scores on symptom and smoking habits.
b
function scales at 10 years ,
WW vs. RT:
Urinary bother: 2.0 vs. 2.8
(P=0.459)
Incontinence: 1.0 vs. 1.5
(P=0.092)
Urinary frequency/day: 6.1 vs.
6.5 (P=0.639)
Nocturia: 2.1 vs. 1.8 (P=0.900)
Starting problems: 1.7 vs. 1.9
(P=0.354)
Pain while urinating: 0.2 vs. 0.4
(P=0.099)
Urgency: 2.3 vs. 2.1 (P=0.750)
Daily activity: 1.6 vs. 1.4
(P=0.984)
Bowel bother: 1.6 vs. 2.7
(P=0.094)
Daily activity: 0.9 vs. 1.3
(P=0.364)

b The study also reported mean symptom/function scores at 4 years of followup; we have extracted information only for the 10 year followup period.

C-179